Microbot Medical (NASDAQ:MBOT) Posts Earnings Results, Meets Expectations

Posted by Francis Steltz on Aug 12th, 2026

Microbot Medical (NASDAQ:MBOT – Get Free Report) issued its earnings results on Tuesday. The biotechnology company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08), FiscalAI reports. The firm had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.33 million.

Microbot Medical Stock Up 3.0%

Shares of MBOT stock traded up $0.05 during mid-day trading on Wednesday, hitting $1.73. The company’s stock had a trading volume of 265,368 shares, compared to its average volume of 1,526,802. The stock has a market cap of $116.20 million, a price-to-earnings ratio of -6.65 and a beta of 1.06. The company has a debt-to-equity ratio of 0.01, a quick ratio of 21.93 and a current ratio of 22.59. Microbot Medical has a 52-week low of $1.60 and a 52-week high of $4.67. The business has a 50-day moving average price of $1.83 and a 200 day moving average price of $2.07.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MBOT shares. Zacks Research upgraded Microbot Medical from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 22nd. HC Wainwright reissued a “buy” rating on shares of Microbot Medical in a research report on Tuesday, July 14th. Loop Capital set a $4.00 price objective on shares of Microbot Medical in a report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a research note on Wednesday, July 8th. Finally, Wall Street Zen raised Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $6.62.

Read Our Latest Stock Report on Microbot Medical

Institutional Investors Weigh In On Microbot Medical

Large investors have recently bought and sold shares of the business. Cetera Investment Advisers boosted its position in Microbot Medical by 38.8% in the fourth quarter. Cetera Investment Advisers now owns 29,313 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 8,201 shares during the last quarter. Zacks Investment Management bought a new position in Microbot Medical in the 3rd quarter worth $33,000. Squarepoint Ops LLC bought a new stake in Microbot Medical during the third quarter valued at about $37,000. American Century Companies Inc. bought a new stake in Microbot Medical during the 2nd quarter valued at approximately $32,000. Finally, Wexford Capital LP purchased a new position in Microbot Medical in the 3rd quarter worth approximately $50,000. 16.30% of the stock is currently owned by institutional investors.

About Microbot Medical

(Get Free Report)

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.